Evidence map›Paper›PMID 40733192›Full record

ArticleMolecules (Basel, Switzerland)2025

From Antiretroviral to Antibacterial: Deep-Learning-Accelerated Repurposing and In Vitro Validation of Efavirenz Against Gram-Positive Bacteria.

Ezzeldin Saleh, Omar A Soliman, Nancy Attia, Nouran Rafaat, Daniel Baecker, Mohamed Teleb, Abeer Ghazal, Ahmed Noby Amer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ezzeldin SalehMicrobiology Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt.
Omar A SolimanDepartment of Clinical Pharmacy, Alexandria University Main Teaching Hospital, Alexandria 21526, Egypt.
Nancy AttiaMicrobiology Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt.
Nouran RafaatDepartment of Infectious Diseases Surveillance, El Amereya Medical Area, Ministry of Health, Alexandria 53330, Egypt.ORCID 0009-0004-6280-6971
Daniel BaeckerDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany.ORCID 0000-0002-1963-9838
Mohamed TelebDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Abeer GhazalMicrobiology Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt.
Ahmed Noby AmerMicrobiology and Immunology Department, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria 21648, Egypt.ORCID 0000-0003-3610-4592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The repurposing potential of Efavirenz (EFV), a clinically established non-nucleoside reverse transcriptase inhibitor, was comprehensively evaluated for its in vitro antibacterial effect either alone or in combination with other antibacterial agents on several Gram-positive clinical strains showing different antibiotic resistance profiles. The binding potential assessed by an in silico study included Penicillin-binding proteins (PBPs) and WalK membrane kinase. Despite the relatively high minimum inhibitory concentration (MIC) limiting the use of EFV as a single antibacterial agent, it exhibits significant synergistic activity at sub-MIC levels when paired with various antibiotics against

Indexed as

Anti-Bacterial AgentsAnti-Retroviral AgentsBenzoxazinesDrug RepositioningGram-Positive BacteriaAlkynesCyclopropanesHumansMicrobial Sensitivity TestsMolecular Docking SimulationAlkynesAnti-Bacterial AgentsAnti-Retroviral AgentsBenzoxazinesCyclopropanesefavirenzantibacterial activitydrug repurposingEfavirenzin silico binding study

Identifiers

PMID40733192
PMCPMC12299921

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.